Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia

Archives of Internal Medicine

Volumn 157, Issue 15, 1997, Pages 1753-1757

  Kerridge, Ian ^a,b,c   Lowe, Michael ^a   Seldon, Michael ^b   Enno, Arno ^b   Deveridge, Sandra ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ERYTHROPOIETIN; TRANEXAMIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; AUTOGRAFT; CASE REPORT; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEDICAL ETHICS; PANCYTOPENIA; PRIORITY JOURNAL; RELIGION; SEPSIS; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030748574     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.15.1753     Document Type: Article

References (26)

1. Watt J. Alternative management procedures should be used. BMJ. 1994;308:1424.
2. Immovable for the right to worship. Watch-tower. 1945;66:195-196.
3. Fontanarosa PB, Giorgio GT. Managing Jehovah's Witnesses: medical, legal, and ethical challenges. Ann Emerg Med. 1991;10:1148-1149.
4. Singelenberg R. The blood transfusion taboo of Jehovah's Witnesses: origin, development and function of a controversial doctrine. Soc Sci Med. 1990;31:515-523.
5. Jonsen AR. Blood transfusion and Jehovah's Witnesses. Crit Care Clin. 1986;2:92-93.
6. Macklin R. The inner workings of an ethics committee: latest battle over Jehovah's Witnesses. Hastings Cent Rep. 1988;18:15-20.
7. Quintero C. Blood administration in pediatric Jehovah's Witnesses. Pediatr Nurs. 1993;19:46-48.
8. Frackiewicz EJ, Lee R. Use of a blood substitute in a patient who refuses to accept a transfusion. Am J Hosp Pharm. 1991;48:2176.
9. Vincent JL. Transfusion in the exsanguinating Jehovah's Witness patient: the attitude of intensivecare doctors. Eur J Anaesthesiol. 1991;8:297-300.
10. Finfer S, Howell S, Millar J, Willett K, Wilson-MacDonald J. Managing patients who refuse blood transfusions: an ethical dilemma. BMJ. 1994;308: 1423-1424.
11. Jones MA. The legal view. BMJ. 1994;308:1425.
12. Randolph v City of New York. A 117,44 (NY Super Ct 1986).
13. Emanuel LL, Emanuel EJ, Stoeckle JD, Hummel LR, Barry MJ. Advance directives: stability of patient's treatment choices. Arch Intern Med. 1994; 154:209-217.
14. Danis M, Garrett J, Harris R, Patrick DL. Stability of choices about life-sustaining treatments. Ann Intern Med. 1994;120:567-573.
15. Jehovah's Witnesses: Their Medical Management. Ingleburn, Australia: Watchtower Bible and Tract Society of Australia; 1992.
16. Nousiainen T, Jantunen E, Lahtinen R. Jehovah's Witnesses and acute leukemia. Am J Hematol. 1993;43:158-159.
17. Goldberg SL, Chan CS, Dawkins FW. Should Jehovah's Witnesses be denied intensive chemotherapy for leukemia. N Engl J Med. 1990;322: 777-778.
18. Dainer PM, Knupp CL, Sartiano GP. Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. Am J Hematol. 1992;40:156-157.
19. Cullis JO, Smith AG. Jehovah's Witnesses with leukaemia. Lancet. 1990;336:1075-1076.
20. Broccia G. Long-term continuous complete remission of acute myeloid leukaemia in Jehovah's Witness treated without blood support. Haematologica. 1994;79:180-181.
21. Boggs DR. Jehovah's Witnesses with leukaemia. Hosp Pract (Off Ed). 1985;20:94-95.
22. Pousada L, Fiorito J, Smyth C. Erythropoietin and anemia of gastrointestinal bleeding in a Jehovah's Witness. Ann Intern Med. 1990;112: 522.
23. Boshkov LK, Tredget EE, Janowska-Wiecxorak A. Recombinant human erythropoietin for a Jehovah's Witness with anemia of thermal origin. Am J Hematol. 1991;37:53-54.
24. Viele MK, Wieskopf RB. What can we learn about the need for transfusion from patients who refuse blood: the experience with Jehovah's Witnesses. Transfusion. 1994;34:396-401.
25. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral blood progenitor cell mobilisation by Filigastrin (GCSF) on platelet recovery after high dose chemotherapy. Lancet. 1992;229:640-644.
26. Nelson BS, Heiskell EE, Cemaj S, O'Callaghan TA, Koller CE. Traumatically injured Jehovah's Witnesses: a sixteen-year experience of treatment and transfusion dilemmas at Level 1 Trauma Center. J Trauma. 1995;39:681-685.